On Thursday, July 25, 2019, the Arthritis Advisory Committee (AAC) discussed a supplemental new drug application (sNDA) for nintedanib capsules (US Trade Name: OFEV), sponsored by Boehringer Ingelheim (BI), for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). A majority of the committee, 10 of 17 members, voted in favor of approval for this proposed use.
Back to All Events
Earlier Event: June 20Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee
Later Event: July 31CANCELLED: Psychopharmacologic Drugs Advisory Committee